Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TorreyPines/Axonyx Merger Will Pursue CNS Disorder Therapies

This article was originally published in The Pink Sheet Daily

Executive Summary

The merged firm will likely seek a licensing partner before submitting an NDA for Axonyx’ Alzheimer’s disease candidate phenserine.

You may also be interested in...



With Five Deals In Two Months, TorreyPines Scrambling To Preserve A Future

California biotech has out-licensed virtually everything but three clinical compounds, while exiting discovery work entirely.

With Five Deals In Two Months, TorreyPines Scrambling To Preserve A Future

California biotech has out-licensed virtually everything but three clinical compounds, while exiting discovery work entirely.

Genentech To Acquire AC Immune’s Beta-Amyloid Antibodies For Alzheimer’s Research

The biotech will pay more than $300 million for preclinical conformation-specific antibodies against beta-amyloid.

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel